medicina58巻3号

2021年03月発行

特集 いまさら聞けない！ 肝胆膵疾患—みなさんのギモンに答えます 肝硬変の診断と合併症に対する治療

サルコペニア・亜鉛欠乏の診断と治療

著者： 平岡淳¹

所属機関： ¹愛媛県立中央病院消化器病センター内科

ページ範囲：P.464 - P.468

　二次性サルコペニアや亜鉛欠乏症は慢性肝疾患の合併症として知られている．これらの慢性肝疾患の合併症に対する対策はQOLや予後の改善において重要である．

参考文献

1）Hiraoka A, et al：Muscle atrophy as pre-sarcopenia in Japanese patients with chronic liver disease；Computed tomography is useful for evaluation. J Gastroenterol 50：1206-1213, 2015

2）Hiraoka A, et al：Sarcopenia and two types of presarcopenia in Japanese patients with chronic liver disease. Eur J Gastroenterol Hepatol 28：940-947, 2016

3）Chang KV, et al：Association between loss of skeletal muscle mass and mortality and tumor recurrence in hepatocellular carcinoma；A systematic review and meta-analysis. Liver Cancer 7：90-103, 2018

4）Leong DP, et al：Prognostic value of grip strength；Findings from the Prospective Urban Rural Epidemiology（PURE）study. Lancet 386：266-273, 2015

5）Hiraoka A, et al：SARC-F combined with a simple tool for assessment of muscle abnormalities in outpatients with chronic liver disease. Hepatol Res 50：502-511, 2020

6）Hayashi F, et al：Nutritional status in relation to lifestyle in patients with compensated viral cirrhosis. World J Gastroenterol 18：5759-5770, 2012

7）Hiraoka A, et al：Efficacy of branched-chain amino acid supplementation and walking exercise for preventing sarcopenia in patients with liver cirrhosis. Eur J Gastroenterol Hepatol 29：1416-1423, 2017

8）Hiraoka A, et al：Can L-carnitine supplementation and exercise improve muscle complications in patients with liver cirrhosis who receive branched-chain amino acid supplementation? Eur J Gastroenterol Hepatol 31：878-884, 2019

9）Ohara M, et al：L-carnitine suppresses loss of skeletal muscle mass in patients with liver cirrhosis. Hepatol Commun 2：906-918, 2018

10）Nishikawa H, et al：Japan Society of Hepatology guidelines for sarcopenia in liver disease（1st edition）；Recommendation from the working group for creation of sarcopenia assessment criteria. Hepatol Res 46：951-963, 2016

11）Hiraoka A, et al：Easy surveillance of muscle volume decline in chronic liver disease patients using finger-circle（yubi-wakka）test. J Cachexia Sarcopenia Muscle 10：347-354, 2019

12）Kodama H, et al：Practice guideline for zinc deficiency. J Jap Soc Clin Nutr 40：120-167, 2018（Abstract in English）

13）Katayama K, et al：The prevalence and implication of zinc deficiency in patients with chronic liver disease. J Clin Med Res 10：437-444, 2018

14）Katayama K, et al：Effect of zinc on liver cirrhosis with hyperammonemia；A preliminary randomized, placebo-controlled double-blind trial. Nutrition 30：1409-1414, 2014

15）Iwata K, et al：Serum zinc value in patients with hepatitis virus-related chronic liver disease；Association with the histological degree of liver fibrosis and with the severity of varices in compensated cirrhosis. J Clin Biochem Nutr 55：147-152, 2014

16）Hiraoka A, et al：Zinc deficiency as an independent prognostic factor for patients with early hepatocellular carcinoma due to hepatitis virus. Hepatol Res 50：92-100, 2020

17）Katayama K：Ammonia metabolism and hepatic encephalopathy. Hepatol Res 30S：73-80, 2004

18）Nishikawa H, et al：Serum zinc concentration and sarcopenia；A close linkage in chronic liver diseases. J Clin Med 8：336, 2019

19）Hosui A, et al：Long-term zinc supplementation improves liver function and decreases the risk of developing hepatocellular carcinoma. Nutrients 10：1955, 2018